Bayer HealthCare and Activaero in inhaled treatment deal
This article was originally published in Scrip
Executive Summary
Bayer HealthCare and German-based Activaero Technologies are to develop preclinical-stage compounds for inhaled treatments. The therapeutic targets and active ingredients have not been disclosed. Under the licensing and option agreement, Activaero will receive an upfront payment and milestone payments if Bayer HealthCare exercises its option; no further financial details were given. Dr Gerhard Scheuch, founder and CEO of Activaero believes that pulmonary administration of drugs has "a huge potential for the treatment of lung diseases and diseases which start in the lung". The company has two products on the market - AKITA, a patient-tailored controlled breathing system with a smartcard that records patient dosing parameters, and Watchhaler, a hand-held delivery system specifically for children. It says it also has other technologies for the controlled delivery of inhaled therapeutics in the clinical setting.